Welcome to our dedicated page for Allarity news (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity stock.
Allarity Therapeutics, Inc. develops personalized cancer treatments as a clinical-stage biopharmaceutical company focused on stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and its DRP® companion diagnostic technology. The company’s updates center on Phase 2 oncology development, advanced ovarian cancer, clinical and scientific data presentations, companion-diagnostic intellectual property, FDA Fast Track status, and potential use of stenoparib in additional tumor settings.
Recurring news also covers operating and financial results, financing activity that supports clinical programs, research collaborations, and governance matters for the Nasdaq-listed company.
Allarity Therapeutics (Nasdaq: ALLR) has entered into licensing agreements with Oncoheroes Biosciences for the development of dovitinib and stenoparib in pediatric cancers. Oncoheroes will fund and advance clinical trials, while Allarity will provide support and supply drug inventory. Allarity submitted a new drug application (NDA) for dovitinib in renal cell carcinoma (RCC), alongside the Dovitinib-DRP® companion diagnostic. The company is also evaluating stenoparib for advanced ovarian cancer. Financial terms of the agreements remain undisclosed.